INTERNATIONAL CONGRESS OF
PharmacoGenetics
Assessment of melanoma metagenome and phenotypic analysis of native mutations in Iran
-
Majid Mesgartehrani,1,* Samereh Khademee,2 Mohammad Mahdi Eslami,3 Karimi,4
1. Iran Genomics Scientific Pole, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Tehran University of Medical Sciences, Tehran, Iran
4. Tehran University of Medical Sciences, Tehran, Iran
- Introduction: Melanoma is a type of disease in which melanocytes, which produce skin pigments, are involved. Melanoma is one of the most common skin cancers, and there are different causes of it. Genetically, melanoma is one of the polymorphismic diseases in which mutations in some organic bases increase the likelihood of a person suffering from this disease.
- Methods: We used the NCBI database to collect and research the genes involved in melanoma and MegaGene pharmacogenetic software to analyze polymorphism information and to detect adverse effects of drugs of genetic origin.
- Results: after examining the genes, we came up with ten important genes (ASIP, BRAF, CDK4, EGF, MC1R, MDM2, NRAS, RB1, TYR and TYRP1). Of these 10 genes, nine (ASIP, BRAF, CDK4, EGF, MC1R, NRAS, RB1, TYR and TYRP1) are involved in about a 90% chance of developing melanoma. Four drugs (Dacacedal, Dacabarzine MEDAC, DTI and Pembrolizumab) had side effects base on genetic origin. The analysis showed that Dacacedal, Dacabarzine MEDAC, and DTI caused nausea by influencing MLH1 gene and Pembrolizumab by influencing ABCC2 gene.
- Conclusion: Therefore, before prescribing therapeutic drugs for melanoma, it is necessary to first perform gene tests to investigate the presence of polymorphisms in common genes such as BRAF, ASIP, CDK4 in order to perform drugs with fewer side effects for the patient in case of polymorphism.
- Keywords: Gene, Melanoma, Pharmacogenetics, Skin cancer, Phenotype
